Inicio・Lista de Acciones・Vir Biotechnology Inc

Vir Biotechnology Inc

Abierto

SectorSanidad

9.37 -0.43

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.27

Máximo

9.57

Métricas clave
By Trading Economics
Ingresos	-83M -126M
Ventas	-64M -29K
BPA	-0.85
Margen de beneficios	433,431.034
Empleados	367
EBITDA	-83M -123M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+127.49% upside

Dividendos
By Acuity
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-85M 1.6B
Apertura anterior	9.8
Cierre anterior	9.37

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

298 / 340 Clasificación en Healthcare

Vir Biotechnology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 17:16 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

20 jul 2026, 21:02 UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Comparación entre iguales

Cambio de precio

Vir Biotechnology Inc previsión

Precio Objetivo

By TipRanks

127.49% repunte

Estimación a 12 Meses

Media 21.43 USD 127.49%

Máximo 30 USD

Mínimo 16 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Vir Biotechnology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Vir Biotechnology Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

298 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.